Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00130351 · ClinicalTrials.gov registry record · Phase 3
A 3-week Study Investigating Patient Use and Functionality of Formoterol in a Novel Inhalation Device in Patients With Asthma
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 155
- Enrollment target
NCT00130351 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 155 participants.
The verdict
NCT00130351, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 155 participants
- Enrollment target
Study Summary
This study is designed to investigate the ability of patients with asthma to properly use a new multi-dose dry powder inhaler (MDDPI) device in a real-life situation.
Interventions
- DEVICE formoterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2005-07 |
| Est. Completion | 2005-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00130351
The ClinicalTrials.gov registry entry for NCT00130351 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which formoterol is the first listed.
NCT00130351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00130351 about?
NCT00130351 is a clinical study titled "A 3-week Study Investigating Patient Use and Functionality of Formoterol in a Novel Inhalation Device in Patients With Asthma". This study is designed to investigate the ability of patients with asthma to properly use a new multi-dose dry powder inhaler (MDDPI) device in a real-life situation.
What is the current status of trial NCT00130351?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 155 participants. The study started on 2005-07. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00130351?
The interventions under investigation include: formoterol (DEVICE).
Who is sponsoring clinical trial NCT00130351?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.